Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.
Identifieur interne : 004555 ( Main/Exploration ); précédent : 004554; suivant : 004556Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.
Auteurs : Lecia V. Sequist [Allemagne] ; James Chih-Hsin Yang ; Nobuyuki Yamamoto ; Kenneth O'Byrne ; Vera Hirsh ; Tony Mok ; Sarayut Lucien Geater ; Sergey Orlov ; Chun-Ming Tsai ; Michael Boyer ; Wu-Chou Su ; Jaafar Bennouna ; Terufumi Kato ; Vera Gorbunova ; Ki Hyeong Lee ; Riyaz Shah ; Dan Massey ; Victoria Zazulina ; Mehdi Shahidi ; Martin SchulerSource :
- Journal of clinical oncology : official journal of the American Society of Clinical Oncology [ 1527-7755 ] ; 2013.
Descripteurs français
- KwdFr :
- Adulte, Adulte d'âge moyen, Adénocarcinome (anatomopathologie), Adénocarcinome (enzymologie), Adénocarcinome (génétique), Adénocarcinome (traitement médicamenteux), Cisplatine (administration et posologie), Cisplatine (effets indésirables), Cisplatine (pharmacocinétique), Femelle, Glutamates (administration et posologie), Glutamates (effets indésirables), Glutamates (pharmacocinétique), Guanine (administration et posologie), Guanine (analogues et dérivés), Guanine (effets indésirables), Guanine (pharmacocinétique), Humains, Mutation, Mâle, Métastase tumorale, Protocoles de polychimiothérapie antinéoplasique (effets indésirables), Protocoles de polychimiothérapie antinéoplasique (pharmacocinétique), Protocoles de polychimiothérapie antinéoplasique (usage thérapeutique), Pémétrexed, Quinazolines (effets indésirables), Quinazolines (pharmacocinétique), Quinazolines (usage thérapeutique), Récepteur du facteur de croissance épidermique (génétique), Sujet âgé, Sujet âgé de 80 ans ou plus, Tumeurs du poumon (anatomopathologie), Tumeurs du poumon (enzymologie), Tumeurs du poumon (génétique), Tumeurs du poumon (traitement médicamenteux).
- MESH :
- administration et posologie : Cisplatine, Glutamates, Guanine.
- analogues et dérivés : Guanine.
- anatomopathologie : Adénocarcinome, Tumeurs du poumon.
- effets indésirables : Cisplatine, Glutamates, Guanine, Protocoles de polychimiothérapie antinéoplasique, Quinazolines.
- enzymologie : Adénocarcinome, Tumeurs du poumon.
- génétique : Adénocarcinome, Récepteur du facteur de croissance épidermique, Tumeurs du poumon.
- pharmacocinétique : Cisplatine, Glutamates, Guanine, Protocoles de polychimiothérapie antinéoplasique, Quinazolines.
- traitement médicamenteux : Adénocarcinome, Tumeurs du poumon.
- usage thérapeutique : Protocoles de polychimiothérapie antinéoplasique, Quinazolines.
- Adulte, Adulte d'âge moyen, Femelle, Humains, Mutation, Mâle, Métastase tumorale, Pémétrexed, Sujet âgé, Sujet âgé de 80 ans ou plus.
English descriptors
- KwdEn :
- Adenocarcinoma (drug therapy), Adenocarcinoma (enzymology), Adenocarcinoma (genetics), Adenocarcinoma (pathology), Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols (adverse effects), Antineoplastic Combined Chemotherapy Protocols (pharmacokinetics), Antineoplastic Combined Chemotherapy Protocols (therapeutic use), Cisplatin (administration & dosage), Cisplatin (adverse effects), Cisplatin (pharmacokinetics), Female, Glutamates (administration & dosage), Glutamates (adverse effects), Glutamates (pharmacokinetics), Guanine (administration & dosage), Guanine (adverse effects), Guanine (analogs & derivatives), Guanine (pharmacokinetics), Humans, Lung Neoplasms (drug therapy), Lung Neoplasms (enzymology), Lung Neoplasms (genetics), Lung Neoplasms (pathology), Male, Middle Aged, Mutation, Neoplasm Metastasis, Pemetrexed, Quinazolines (adverse effects), Quinazolines (pharmacokinetics), Quinazolines (therapeutic use), Receptor, Epidermal Growth Factor (genetics).
- MESH :
- chemical , administration & dosage : Cisplatin, Glutamates, Guanine.
- adverse effects : Antineoplastic Combined Chemotherapy Protocols, Cisplatin, Glutamates, Guanine, Quinazolines.
- chemical , analogs & derivatives : Guanine.
- drug therapy : Adenocarcinoma, Lung Neoplasms.
- enzymology : Adenocarcinoma, Lung Neoplasms.
- genetics : Adenocarcinoma, Lung Neoplasms, Receptor, Epidermal Growth Factor.
- pathology : Adenocarcinoma, Lung Neoplasms.
- pharmacokinetics : Antineoplastic Combined Chemotherapy Protocols, Cisplatin, Glutamates, Guanine, Quinazolines.
- therapeutic use : Antineoplastic Combined Chemotherapy Protocols, Quinazolines.
- Adult, Aged, Aged, 80 and over, Female, Humans, Male, Middle Aged, Mutation, Neoplasm Metastasis, Pemetrexed.
Abstract
The LUX-Lung 3 study investigated the efficacy of chemotherapy compared with afatinib, a selective, orally bioavailable ErbB family blocker that irreversibly blocks signaling from epidermal growth factor receptor (EGFR/ErbB1), human epidermal growth factor receptor 2 (HER2/ErbB2), and ErbB4 and has wide-spectrum preclinical activity against EGFR mutations. A phase II study of afatinib in EGFR mutation-positive lung adenocarcinoma demonstrated high response rates and progression-free survival (PFS).
DOI: 10.1200/JCO.2012.44.2806
PubMed: 23816960
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 003B22
- to stream PubMed, to step Curation: 003992
- to stream PubMed, to step Checkpoint: 003992
- to stream Ncbi, to step Merge: 001339
- to stream Ncbi, to step Curation: 001339
- to stream Ncbi, to step Checkpoint: 001339
- to stream Main, to step Merge: 004648
- to stream Main, to step Curation: 004555
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.</title><author><name sortKey="Sequist, Lecia V" sort="Sequist, Lecia V" uniqKey="Sequist L" first="Lecia V" last="Sequist">Lecia V. Sequist</name><affiliation wicri:level="1"><nlm:affiliation>Lecia V. Sequist, Massachusetts General Hospital and Harvard Medical School, Boston, MA; James Chih-Hsin Yang, National Taiwan University Hospital; Chun-Ming Tsai, Taipei Veterans General Hospital, Taipei; Wu-Chou Su, National Cheng Kung University Hospital, Tainan, Taiwan; Nobuyuki Yamamoto, Shizuoka Cancer Center, Shizuoka; Terufumi Kato, Kanagawa Cardiovascular and Respiratory Center, Yokohama, Japan; Kenneth O'Byrne, St James' Hospital, Dublin, Ireland; Vera Hirsh, McGill University, Montreal, Quebec, Canada; Tony Mok, Prince of Wales Hospital, Hong Kong, China; Sarayut Lucien Geater, Songklanagarind Hospital, Songkla, Thailand; Sergey Orlov, Pavlov State Medical University, St Petersburg; Vera Gorbunova, GU Russian Oncological Research Centre, Moscow, Russia; Michael Boyer, Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia; Jaafar Bennouna, Institut de Cancérologie de l'Ouest-site René Gauducheau, Nantes, France; Ki Hyeong Lee, Chungbuk National University Hospital, Cheongju, South Korea; Riyaz Shah, Maidstone and Tunbridge Wells National Health Service Trust, Maidstone Hospital, Maidstone; Dan Massey, Victoria Zazulina, and Mehdi Shahidi, Boehringer Ingelheim, Bracknell, United Kingdom; and Martin Schuler, West German Cancer Center, University of Duisburg-Essen, Essen, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Lecia V. Sequist, Massachusetts General Hospital and Harvard Medical School, Boston, MA; James Chih-Hsin Yang, National Taiwan University Hospital; Chun-Ming Tsai, Taipei Veterans General Hospital, Taipei; Wu-Chou Su, National Cheng Kung University Hospital, Tainan, Taiwan; Nobuyuki Yamamoto, Shizuoka Cancer Center, Shizuoka; Terufumi Kato, Kanagawa Cardiovascular and Respiratory Center, Yokohama, Japan; Kenneth O'Byrne, St James' Hospital, Dublin, Ireland; Vera Hirsh, McGill University, Montreal, Quebec, Canada; Tony Mok, Prince of Wales Hospital, Hong Kong, China; Sarayut Lucien Geater, Songklanagarind Hospital, Songkla, Thailand; Sergey Orlov, Pavlov State Medical University, St Petersburg; Vera Gorbunova, GU Russian Oncological Research Centre, Moscow, Russia; Michael Boyer, Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia; Jaafar Bennouna, Institut de Cancérologie de l'Ouest-site René Gauducheau, Nantes, France; Ki Hyeong Lee, Chungbuk National University Hospital, Cheongju, South Korea; Riyaz Shah, Maidstone and Tunbridge Wells National Health Service Trust, Maidstone Hospital, Maidstone; Dan Massey, Victoria Zazulina, and Mehdi Shahidi, Boehringer Ingelheim, Bracknell, United Kingdom; and Martin Schuler, West German Cancer Center, University of Duisburg-Essen, Essen</wicri:regionArea><wicri:noRegion>Essen</wicri:noRegion><wicri:noRegion>Essen</wicri:noRegion><wicri:noRegion>Essen</wicri:noRegion></affiliation></author><author><name sortKey="Yang, James Chih Hsin" sort="Yang, James Chih Hsin" uniqKey="Yang J" first="James Chih-Hsin" last="Yang">James Chih-Hsin Yang</name></author><author><name sortKey="Yamamoto, Nobuyuki" sort="Yamamoto, Nobuyuki" uniqKey="Yamamoto N" first="Nobuyuki" last="Yamamoto">Nobuyuki Yamamoto</name></author><author><name sortKey="O Byrne, Kenneth" sort="O Byrne, Kenneth" uniqKey="O Byrne K" first="Kenneth" last="O'Byrne">Kenneth O'Byrne</name></author><author><name sortKey="Hirsh, Vera" sort="Hirsh, Vera" uniqKey="Hirsh V" first="Vera" last="Hirsh">Vera Hirsh</name></author><author><name sortKey="Mok, Tony" sort="Mok, Tony" uniqKey="Mok T" first="Tony" last="Mok">Tony Mok</name></author><author><name sortKey="Geater, Sarayut Lucien" sort="Geater, Sarayut Lucien" uniqKey="Geater S" first="Sarayut Lucien" last="Geater">Sarayut Lucien Geater</name></author><author><name sortKey="Orlov, Sergey" sort="Orlov, Sergey" uniqKey="Orlov S" first="Sergey" last="Orlov">Sergey Orlov</name></author><author><name sortKey="Tsai, Chun Ming" sort="Tsai, Chun Ming" uniqKey="Tsai C" first="Chun-Ming" last="Tsai">Chun-Ming Tsai</name></author><author><name sortKey="Boyer, Michael" sort="Boyer, Michael" uniqKey="Boyer M" first="Michael" last="Boyer">Michael Boyer</name></author><author><name sortKey="Su, Wu Chou" sort="Su, Wu Chou" uniqKey="Su W" first="Wu-Chou" last="Su">Wu-Chou Su</name></author><author><name sortKey="Bennouna, Jaafar" sort="Bennouna, Jaafar" uniqKey="Bennouna J" first="Jaafar" last="Bennouna">Jaafar Bennouna</name></author><author><name sortKey="Kato, Terufumi" sort="Kato, Terufumi" uniqKey="Kato T" first="Terufumi" last="Kato">Terufumi Kato</name></author><author><name sortKey="Gorbunova, Vera" sort="Gorbunova, Vera" uniqKey="Gorbunova V" first="Vera" last="Gorbunova">Vera Gorbunova</name></author><author><name sortKey="Lee, Ki Hyeong" sort="Lee, Ki Hyeong" uniqKey="Lee K" first="Ki Hyeong" last="Lee">Ki Hyeong Lee</name></author><author><name sortKey="Shah, Riyaz" sort="Shah, Riyaz" uniqKey="Shah R" first="Riyaz" last="Shah">Riyaz Shah</name></author><author><name sortKey="Massey, Dan" sort="Massey, Dan" uniqKey="Massey D" first="Dan" last="Massey">Dan Massey</name></author><author><name sortKey="Zazulina, Victoria" sort="Zazulina, Victoria" uniqKey="Zazulina V" first="Victoria" last="Zazulina">Victoria Zazulina</name></author><author><name sortKey="Shahidi, Mehdi" sort="Shahidi, Mehdi" uniqKey="Shahidi M" first="Mehdi" last="Shahidi">Mehdi Shahidi</name></author><author><name sortKey="Schuler, Martin" sort="Schuler, Martin" uniqKey="Schuler M" first="Martin" last="Schuler">Martin Schuler</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2013">2013</date><idno type="RBID">pubmed:23816960</idno><idno type="pmid">23816960</idno><idno type="doi">10.1200/JCO.2012.44.2806</idno><idno type="wicri:Area/PubMed/Corpus">003B22</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">003B22</idno><idno type="wicri:Area/PubMed/Curation">003992</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">003992</idno><idno type="wicri:Area/PubMed/Checkpoint">003992</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">003992</idno><idno type="wicri:Area/Ncbi/Merge">001339</idno><idno type="wicri:Area/Ncbi/Curation">001339</idno><idno type="wicri:Area/Ncbi/Checkpoint">001339</idno><idno type="wicri:Area/Main/Merge">004648</idno><idno type="wicri:Area/Main/Curation">004555</idno><idno type="wicri:Area/Main/Exploration">004555</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.</title><author><name sortKey="Sequist, Lecia V" sort="Sequist, Lecia V" uniqKey="Sequist L" first="Lecia V" last="Sequist">Lecia V. Sequist</name><affiliation wicri:level="1"><nlm:affiliation>Lecia V. Sequist, Massachusetts General Hospital and Harvard Medical School, Boston, MA; James Chih-Hsin Yang, National Taiwan University Hospital; Chun-Ming Tsai, Taipei Veterans General Hospital, Taipei; Wu-Chou Su, National Cheng Kung University Hospital, Tainan, Taiwan; Nobuyuki Yamamoto, Shizuoka Cancer Center, Shizuoka; Terufumi Kato, Kanagawa Cardiovascular and Respiratory Center, Yokohama, Japan; Kenneth O'Byrne, St James' Hospital, Dublin, Ireland; Vera Hirsh, McGill University, Montreal, Quebec, Canada; Tony Mok, Prince of Wales Hospital, Hong Kong, China; Sarayut Lucien Geater, Songklanagarind Hospital, Songkla, Thailand; Sergey Orlov, Pavlov State Medical University, St Petersburg; Vera Gorbunova, GU Russian Oncological Research Centre, Moscow, Russia; Michael Boyer, Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia; Jaafar Bennouna, Institut de Cancérologie de l'Ouest-site René Gauducheau, Nantes, France; Ki Hyeong Lee, Chungbuk National University Hospital, Cheongju, South Korea; Riyaz Shah, Maidstone and Tunbridge Wells National Health Service Trust, Maidstone Hospital, Maidstone; Dan Massey, Victoria Zazulina, and Mehdi Shahidi, Boehringer Ingelheim, Bracknell, United Kingdom; and Martin Schuler, West German Cancer Center, University of Duisburg-Essen, Essen, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Lecia V. Sequist, Massachusetts General Hospital and Harvard Medical School, Boston, MA; James Chih-Hsin Yang, National Taiwan University Hospital; Chun-Ming Tsai, Taipei Veterans General Hospital, Taipei; Wu-Chou Su, National Cheng Kung University Hospital, Tainan, Taiwan; Nobuyuki Yamamoto, Shizuoka Cancer Center, Shizuoka; Terufumi Kato, Kanagawa Cardiovascular and Respiratory Center, Yokohama, Japan; Kenneth O'Byrne, St James' Hospital, Dublin, Ireland; Vera Hirsh, McGill University, Montreal, Quebec, Canada; Tony Mok, Prince of Wales Hospital, Hong Kong, China; Sarayut Lucien Geater, Songklanagarind Hospital, Songkla, Thailand; Sergey Orlov, Pavlov State Medical University, St Petersburg; Vera Gorbunova, GU Russian Oncological Research Centre, Moscow, Russia; Michael Boyer, Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia; Jaafar Bennouna, Institut de Cancérologie de l'Ouest-site René Gauducheau, Nantes, France; Ki Hyeong Lee, Chungbuk National University Hospital, Cheongju, South Korea; Riyaz Shah, Maidstone and Tunbridge Wells National Health Service Trust, Maidstone Hospital, Maidstone; Dan Massey, Victoria Zazulina, and Mehdi Shahidi, Boehringer Ingelheim, Bracknell, United Kingdom; and Martin Schuler, West German Cancer Center, University of Duisburg-Essen, Essen</wicri:regionArea><wicri:noRegion>Essen</wicri:noRegion><wicri:noRegion>Essen</wicri:noRegion><wicri:noRegion>Essen</wicri:noRegion></affiliation></author><author><name sortKey="Yang, James Chih Hsin" sort="Yang, James Chih Hsin" uniqKey="Yang J" first="James Chih-Hsin" last="Yang">James Chih-Hsin Yang</name></author><author><name sortKey="Yamamoto, Nobuyuki" sort="Yamamoto, Nobuyuki" uniqKey="Yamamoto N" first="Nobuyuki" last="Yamamoto">Nobuyuki Yamamoto</name></author><author><name sortKey="O Byrne, Kenneth" sort="O Byrne, Kenneth" uniqKey="O Byrne K" first="Kenneth" last="O'Byrne">Kenneth O'Byrne</name></author><author><name sortKey="Hirsh, Vera" sort="Hirsh, Vera" uniqKey="Hirsh V" first="Vera" last="Hirsh">Vera Hirsh</name></author><author><name sortKey="Mok, Tony" sort="Mok, Tony" uniqKey="Mok T" first="Tony" last="Mok">Tony Mok</name></author><author><name sortKey="Geater, Sarayut Lucien" sort="Geater, Sarayut Lucien" uniqKey="Geater S" first="Sarayut Lucien" last="Geater">Sarayut Lucien Geater</name></author><author><name sortKey="Orlov, Sergey" sort="Orlov, Sergey" uniqKey="Orlov S" first="Sergey" last="Orlov">Sergey Orlov</name></author><author><name sortKey="Tsai, Chun Ming" sort="Tsai, Chun Ming" uniqKey="Tsai C" first="Chun-Ming" last="Tsai">Chun-Ming Tsai</name></author><author><name sortKey="Boyer, Michael" sort="Boyer, Michael" uniqKey="Boyer M" first="Michael" last="Boyer">Michael Boyer</name></author><author><name sortKey="Su, Wu Chou" sort="Su, Wu Chou" uniqKey="Su W" first="Wu-Chou" last="Su">Wu-Chou Su</name></author><author><name sortKey="Bennouna, Jaafar" sort="Bennouna, Jaafar" uniqKey="Bennouna J" first="Jaafar" last="Bennouna">Jaafar Bennouna</name></author><author><name sortKey="Kato, Terufumi" sort="Kato, Terufumi" uniqKey="Kato T" first="Terufumi" last="Kato">Terufumi Kato</name></author><author><name sortKey="Gorbunova, Vera" sort="Gorbunova, Vera" uniqKey="Gorbunova V" first="Vera" last="Gorbunova">Vera Gorbunova</name></author><author><name sortKey="Lee, Ki Hyeong" sort="Lee, Ki Hyeong" uniqKey="Lee K" first="Ki Hyeong" last="Lee">Ki Hyeong Lee</name></author><author><name sortKey="Shah, Riyaz" sort="Shah, Riyaz" uniqKey="Shah R" first="Riyaz" last="Shah">Riyaz Shah</name></author><author><name sortKey="Massey, Dan" sort="Massey, Dan" uniqKey="Massey D" first="Dan" last="Massey">Dan Massey</name></author><author><name sortKey="Zazulina, Victoria" sort="Zazulina, Victoria" uniqKey="Zazulina V" first="Victoria" last="Zazulina">Victoria Zazulina</name></author><author><name sortKey="Shahidi, Mehdi" sort="Shahidi, Mehdi" uniqKey="Shahidi M" first="Mehdi" last="Shahidi">Mehdi Shahidi</name></author><author><name sortKey="Schuler, Martin" sort="Schuler, Martin" uniqKey="Schuler M" first="Martin" last="Schuler">Martin Schuler</name></author></analytic><series><title level="j">Journal of clinical oncology : official journal of the American Society of Clinical Oncology</title><idno type="eISSN">1527-7755</idno><imprint><date when="2013" type="published">2013</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adenocarcinoma (drug therapy)</term><term>Adenocarcinoma (enzymology)</term><term>Adenocarcinoma (genetics)</term><term>Adenocarcinoma (pathology)</term><term>Adult</term><term>Aged</term><term>Aged, 80 and over</term><term>Antineoplastic Combined Chemotherapy Protocols (adverse effects)</term><term>Antineoplastic Combined Chemotherapy Protocols (pharmacokinetics)</term><term>Antineoplastic Combined Chemotherapy Protocols (therapeutic use)</term><term>Cisplatin (administration & dosage)</term><term>Cisplatin (adverse effects)</term><term>Cisplatin (pharmacokinetics)</term><term>Female</term><term>Glutamates (administration & dosage)</term><term>Glutamates (adverse effects)</term><term>Glutamates (pharmacokinetics)</term><term>Guanine (administration & dosage)</term><term>Guanine (adverse effects)</term><term>Guanine (analogs & derivatives)</term><term>Guanine (pharmacokinetics)</term><term>Humans</term><term>Lung Neoplasms (drug therapy)</term><term>Lung Neoplasms (enzymology)</term><term>Lung Neoplasms (genetics)</term><term>Lung Neoplasms (pathology)</term><term>Male</term><term>Middle Aged</term><term>Mutation</term><term>Neoplasm Metastasis</term><term>Pemetrexed</term><term>Quinazolines (adverse effects)</term><term>Quinazolines (pharmacokinetics)</term><term>Quinazolines (therapeutic use)</term><term>Receptor, Epidermal Growth Factor (genetics)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Adulte</term><term>Adulte d'âge moyen</term><term>Adénocarcinome (anatomopathologie)</term><term>Adénocarcinome (enzymologie)</term><term>Adénocarcinome (génétique)</term><term>Adénocarcinome (traitement médicamenteux)</term><term>Cisplatine (administration et posologie)</term><term>Cisplatine (effets indésirables)</term><term>Cisplatine (pharmacocinétique)</term><term>Femelle</term><term>Glutamates (administration et posologie)</term><term>Glutamates (effets indésirables)</term><term>Glutamates (pharmacocinétique)</term><term>Guanine (administration et posologie)</term><term>Guanine (analogues et dérivés)</term><term>Guanine (effets indésirables)</term><term>Guanine (pharmacocinétique)</term><term>Humains</term><term>Mutation</term><term>Mâle</term><term>Métastase tumorale</term><term>Protocoles de polychimiothérapie antinéoplasique (effets indésirables)</term><term>Protocoles de polychimiothérapie antinéoplasique (pharmacocinétique)</term><term>Protocoles de polychimiothérapie antinéoplasique (usage thérapeutique)</term><term>Pémétrexed</term><term>Quinazolines (effets indésirables)</term><term>Quinazolines (pharmacocinétique)</term><term>Quinazolines (usage thérapeutique)</term><term>Récepteur du facteur de croissance épidermique (génétique)</term><term>Sujet âgé</term><term>Sujet âgé de 80 ans ou plus</term><term>Tumeurs du poumon (anatomopathologie)</term><term>Tumeurs du poumon (enzymologie)</term><term>Tumeurs du poumon (génétique)</term><term>Tumeurs du poumon (traitement médicamenteux)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Cisplatin</term><term>Glutamates</term><term>Guanine</term></keywords><keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Cisplatine</term><term>Glutamates</term><term>Guanine</term></keywords><keywords scheme="MESH" qualifier="adverse effects" xml:lang="en"><term>Antineoplastic Combined Chemotherapy Protocols</term><term>Cisplatin</term><term>Glutamates</term><term>Guanine</term><term>Quinazolines</term></keywords><keywords scheme="MESH" type="chemical" qualifier="analogs & derivatives" xml:lang="en"><term>Guanine</term></keywords><keywords scheme="MESH" qualifier="analogues et dérivés" xml:lang="fr"><term>Guanine</term></keywords><keywords scheme="MESH" qualifier="anatomopathologie" xml:lang="fr"><term>Adénocarcinome</term><term>Tumeurs du poumon</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Adenocarcinoma</term><term>Lung Neoplasms</term></keywords><keywords scheme="MESH" qualifier="effets indésirables" xml:lang="fr"><term>Cisplatine</term><term>Glutamates</term><term>Guanine</term><term>Protocoles de polychimiothérapie antinéoplasique</term><term>Quinazolines</term></keywords><keywords scheme="MESH" qualifier="enzymologie" xml:lang="fr"><term>Adénocarcinome</term><term>Tumeurs du poumon</term></keywords><keywords scheme="MESH" qualifier="enzymology" xml:lang="en"><term>Adenocarcinoma</term><term>Lung Neoplasms</term></keywords><keywords scheme="MESH" qualifier="genetics" xml:lang="en"><term>Adenocarcinoma</term><term>Lung Neoplasms</term><term>Receptor, Epidermal Growth Factor</term></keywords><keywords scheme="MESH" qualifier="génétique" xml:lang="fr"><term>Adénocarcinome</term><term>Récepteur du facteur de croissance épidermique</term><term>Tumeurs du poumon</term></keywords><keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Adenocarcinoma</term><term>Lung Neoplasms</term></keywords><keywords scheme="MESH" qualifier="pharmacocinétique" xml:lang="fr"><term>Cisplatine</term><term>Glutamates</term><term>Guanine</term><term>Protocoles de polychimiothérapie antinéoplasique</term><term>Quinazolines</term></keywords><keywords scheme="MESH" qualifier="pharmacokinetics" xml:lang="en"><term>Antineoplastic Combined Chemotherapy Protocols</term><term>Cisplatin</term><term>Glutamates</term><term>Guanine</term><term>Quinazolines</term></keywords><keywords scheme="MESH" qualifier="therapeutic use" xml:lang="en"><term>Antineoplastic Combined Chemotherapy Protocols</term><term>Quinazolines</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Adénocarcinome</term><term>Tumeurs du poumon</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Protocoles de polychimiothérapie antinéoplasique</term><term>Quinazolines</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Aged</term><term>Aged, 80 and over</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Mutation</term><term>Neoplasm Metastasis</term><term>Pemetrexed</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Adulte</term><term>Adulte d'âge moyen</term><term>Femelle</term><term>Humains</term><term>Mutation</term><term>Mâle</term><term>Métastase tumorale</term><term>Pémétrexed</term><term>Sujet âgé</term><term>Sujet âgé de 80 ans ou plus</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The LUX-Lung 3 study investigated the efficacy of chemotherapy compared with afatinib, a selective, orally bioavailable ErbB family blocker that irreversibly blocks signaling from epidermal growth factor receptor (EGFR/ErbB1), human epidermal growth factor receptor 2 (HER2/ErbB2), and ErbB4 and has wide-spectrum preclinical activity against EGFR mutations. A phase II study of afatinib in EGFR mutation-positive lung adenocarcinoma demonstrated high response rates and progression-free survival (PFS).</div></front></TEI><affiliations><list><country><li>Allemagne</li></country></list><tree><noCountry><name sortKey="Bennouna, Jaafar" sort="Bennouna, Jaafar" uniqKey="Bennouna J" first="Jaafar" last="Bennouna">Jaafar Bennouna</name><name sortKey="Boyer, Michael" sort="Boyer, Michael" uniqKey="Boyer M" first="Michael" last="Boyer">Michael Boyer</name><name sortKey="Geater, Sarayut Lucien" sort="Geater, Sarayut Lucien" uniqKey="Geater S" first="Sarayut Lucien" last="Geater">Sarayut Lucien Geater</name><name sortKey="Gorbunova, Vera" sort="Gorbunova, Vera" uniqKey="Gorbunova V" first="Vera" last="Gorbunova">Vera Gorbunova</name><name sortKey="Hirsh, Vera" sort="Hirsh, Vera" uniqKey="Hirsh V" first="Vera" last="Hirsh">Vera Hirsh</name><name sortKey="Kato, Terufumi" sort="Kato, Terufumi" uniqKey="Kato T" first="Terufumi" last="Kato">Terufumi Kato</name><name sortKey="Lee, Ki Hyeong" sort="Lee, Ki Hyeong" uniqKey="Lee K" first="Ki Hyeong" last="Lee">Ki Hyeong Lee</name><name sortKey="Massey, Dan" sort="Massey, Dan" uniqKey="Massey D" first="Dan" last="Massey">Dan Massey</name><name sortKey="Mok, Tony" sort="Mok, Tony" uniqKey="Mok T" first="Tony" last="Mok">Tony Mok</name><name sortKey="O Byrne, Kenneth" sort="O Byrne, Kenneth" uniqKey="O Byrne K" first="Kenneth" last="O'Byrne">Kenneth O'Byrne</name><name sortKey="Orlov, Sergey" sort="Orlov, Sergey" uniqKey="Orlov S" first="Sergey" last="Orlov">Sergey Orlov</name><name sortKey="Schuler, Martin" sort="Schuler, Martin" uniqKey="Schuler M" first="Martin" last="Schuler">Martin Schuler</name><name sortKey="Shah, Riyaz" sort="Shah, Riyaz" uniqKey="Shah R" first="Riyaz" last="Shah">Riyaz Shah</name><name sortKey="Shahidi, Mehdi" sort="Shahidi, Mehdi" uniqKey="Shahidi M" first="Mehdi" last="Shahidi">Mehdi Shahidi</name><name sortKey="Su, Wu Chou" sort="Su, Wu Chou" uniqKey="Su W" first="Wu-Chou" last="Su">Wu-Chou Su</name><name sortKey="Tsai, Chun Ming" sort="Tsai, Chun Ming" uniqKey="Tsai C" first="Chun-Ming" last="Tsai">Chun-Ming Tsai</name><name sortKey="Yamamoto, Nobuyuki" sort="Yamamoto, Nobuyuki" uniqKey="Yamamoto N" first="Nobuyuki" last="Yamamoto">Nobuyuki Yamamoto</name><name sortKey="Yang, James Chih Hsin" sort="Yang, James Chih Hsin" uniqKey="Yang J" first="James Chih-Hsin" last="Yang">James Chih-Hsin Yang</name><name sortKey="Zazulina, Victoria" sort="Zazulina, Victoria" uniqKey="Zazulina V" first="Victoria" last="Zazulina">Victoria Zazulina</name></noCountry><country name="Allemagne"><noRegion><name sortKey="Sequist, Lecia V" sort="Sequist, Lecia V" uniqKey="Sequist L" first="Lecia V" last="Sequist">Lecia V. Sequist</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 004555 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 004555 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:23816960
|texte= Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:23816960" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a AustralieFrV1
| This area was generated with Dilib version V0.6.33. |  |